SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Angel Gonzalez Gay Miguel)
 

Search: WFRF:(Angel Gonzalez Gay Miguel) > Biological use infl...

Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis

Karpouzas, George Athanasios (author)
Internal Medicine - Rheumatology, CA, Torrance, United States; Harbor-UCLA Medical Center, Rheumatology, CA, Torrance, United States
Ormseth, Sarah R. (author)
CA, Torrance, United States
van Riel, Piet Leonardus Cornelis Maria (author)
IQ Healthcare, Radboud University, Gelderland, Nijmegen, Netherlands; Bernhoven Hospital Location Oss, Rheumatology, Oss, Netherlands
show more...
Gonzalez-Gay, Miguel A. (author)
Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain; IIS-Fundacion Jimenez Diaz, Madrid, Spain
Corrales, Alfonso (author)
Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Rantapää-Dahlqvist, Solbritt (author)
Umeå universitet,Reumatologi
Sfikakis, Petros P. (author)
First Dept. of Propedeutic Medicine, University of Athens, Attica, Athens, Greece
Dessein, Patrick (author)
School of Physiology, University of the Witwatersrand Johannesburg, Johannesburg, South Africa
Tsang, Linda (author)
Vrije Universiteit Brussel, Belgium
Hitchon, Carol (author)
University of Manitoba, Rheumatology, MB, Winnipeg, Canada
El-Gabalawy, Hani (author)
Department of Internal Medicine, University of Manitoba, MB, Winnipeg, Canada
Pascual-Ramos, Virginia (author)
Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Contreras-Yáñez, Irazú (author)
Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Mexico
Colunga-Pedraza, Iris J. (author)
Hospital Universitario Dr José Eleuterio González, Rheumatology, Nuevo León, Monterrey, Mexico
Galarza-Delgado, Dionicio Angel (author)
Hospital Universitario Dr Jose Eleuterio Gonzalez, Rheumatology, Nuevo León, Monterrey, Mexico
Azpiri-Lopez, Jose Ramon (author)
Hospital Universitario Dr José Eleuterio González, Nuevo León, Monterrey, Mexico
Semb, Anne Grete (author)
Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway
Misra, Durga Prasanna (author)
Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Uttar Pradesh, Lucknow, India
Hauge, Ellen-Margrethe (author)
Department of Joint and Connective Tissue Diseases, Aarhus Universitetshospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus Universitet, Aarhus, Denmark
Kitas, George (author)
Department of Rheumatology, Dudley Group NHS Foundation Trust, West Midlands, Dudley, United Kingdom
show less...
 (creator_code:org_t)
BMJ Publishing Group Ltd, 2024
2024
English.
In: RMD Open. - : BMJ Publishing Group Ltd. - 2056-5933. ; 10:3
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Objectives: Chronic inflammation promotes cardiovascular risk in rheumatoid arthritis (RA). Biological disease-modifying antirheumatic drugs (bDMARDs) improve disease activity and cardiovascular disease outcomes. We explored whether bDMARDs influence the impact of disease activity and inflammatory markers on long-term cardiovascular risk in RA.Methods: We studied 4370 participants without cardiovascular disease in a 10-country observational cohort of patients with RA. Endpoints were (1) major adverse cardiovascular events (MACE) encompassing myocardial infarction, stroke and cardiovascular death; and (2) any ischaemic cardiovascular events (iCVE) including MACE plus revascularisation, angina, transient ischaemic attack and peripheral arterial disease.Results: Over 26 534 patient-years, 239 MACE and 362 iCVE occurred. The interaction between 28-joint Disease Activity Score with C-reactive protein (DAS28-CRP) and bDMARD use was significant for MACE (p=0.017), suggesting the effect of DAS28-CRP on MACE risk differed among bDMARD users (n=515) and non-users (n=3855). DAS28-CRP (per unit increase) is associated with MACE risk in bDMARD non-users (HR 1.21 (95% CI 1.07 to 1.37)) but not users (HR 0.69 (95% CI 0.40 to 1.20)). The interaction between CRP (per log unit increase) and bDMARD use was also significant for MACE (p=0.011). CRP associated with MACE risk in bDMARD non-users (HR 1.16 (95% CI 1.04 to 1.30)), but not users (HR 0.65 (95% CI 0.36 to 1.17)). No interaction was observed between bDMARD use and DAS28-CRP (p=0.167) or CRP (p=0.237) for iCVE risk.Conclusions: RA activity and inflammatory markers associated with risk of MACE in bDMARD non-users but not users suggesting the possibility of biological-specific benefits locally on arterial wall independently of effects on systemic inflammation.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)

Keyword

Arthritis
Rheumatoid
Biological Therapy
Cardiovascular Diseases
Inflammation

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • RMD Open (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view